Last reviewed · How we verify

NCT04808830

Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension

Completed Last updated 18 June 2021
What this trial tests

trial testing Evaluation of musculoskeletal pain prevalence in Pulmonary Arterial Hypertension in 61 participants. Completed in 15 June 2021.

Timeline
25 March 2021
Primary endpoint
15 June 2021
15 June 2021

Quick facts

Lead sponsorIzmir Bakircay University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment61
Start date25 March 2021
Primary completion15 June 2021
Estimated completion15 June 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Izmir Bakircay University

Who can join

Adults 18 to 99, any sex, with Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise capacity will be evaluated in patients with pulmonary arterial hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pulmonary Arterial Hypertension

Currently open trials in the same condition.

Other Izmir Bakircay University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04808830.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing